We have located links that may give you full text access.
Alcohol sclerotherapy of human immunodeficiency virus related parotid lymphoepithelial cysts.
Journal of Laryngology and Otology 2009 April
OBJECTIVE: The aim of the study was to determine the effectiveness of alcohol sclerotherapy in patients with human immunodeficiency virus related salivary gland disease.
STUDY DESIGN: Prospective study investigating the effectiveness of alcohol as a sclerosing agent.
SETTING: Tertiary referral hospital.
PATIENTS: Eleven human immunodeficiency virus positive patients with benign lymphoepithelial cysts were included in the study, from July 2005 to September 2006.
INTERVENTIONS: Alcohol sclerotherapy was performed under local anaesthesia, with alcohol infiltrated into the benign lymphoepithelial cysts.
RESULTS: Alcohol injection sclerotherapy proved to be an effective, simple, cheap, ambulatory procedure for patients who did not qualify for antiretroviral treatment.
STUDY DESIGN: Prospective study investigating the effectiveness of alcohol as a sclerosing agent.
SETTING: Tertiary referral hospital.
PATIENTS: Eleven human immunodeficiency virus positive patients with benign lymphoepithelial cysts were included in the study, from July 2005 to September 2006.
INTERVENTIONS: Alcohol sclerotherapy was performed under local anaesthesia, with alcohol infiltrated into the benign lymphoepithelial cysts.
RESULTS: Alcohol injection sclerotherapy proved to be an effective, simple, cheap, ambulatory procedure for patients who did not qualify for antiretroviral treatment.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app